34 recruiting, 21 completed, 17 active not recruiting, 13 not yet recruiting. 102 Phase 2, 19 Phase 1, 10 Phase 3.
Follow blinatumomab: new trials by email Literature Review of blinatumomab trials Research Report on blinatumomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-12-01 | 2026-11-09 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-11-02 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO) - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 22 | 2026-10-12 | 2026-09-25 |
| Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome Blinatumomab, background treatment - Primary Sjögren's Syndrome (pSS) | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 12 | 2026-09-25 | 2026-10-01 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-11-12 |
| Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab - Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-06-12 | 2026-06-11 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-11-10 |
| A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia BCL-2 indibitor, Azacitidine (AZA), Blinatumomab - Newly Diagnosed Mixed Phenotype Acute Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 52 | 2026-05-01 | 2026-05-07 |
| Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia Blinatumomab - Phase 2 Study, Blinatumomab | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2026-04-21 | 2026-11-12 |
| ALL Backbone in AYAs Blinatumomab, Oncaspar, Cyclophosphamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 67 | 2026-04-03 | 2026-08-17 |
| CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL Capivasertib, Venetoclax, Rituximab - Leukemia, Lymphoma | Phase 1 / Phase 2 | Recruiting | University of Chicago | 104 | 2026-03-17 | 2026-03-04 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) Subcutaneous Blinatumomab - CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL) | Phase 2 | Recruiting | West Virginia University | 78 | 2026-01-15 | 2026-04-13 |
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Amgen | 104 | 2025-12-08 | 2026-10-05 |
| Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL Blinatumomab plus Reduced-dose Chemotherapy - Acute Lymphoid Leukemia (ALL) | Phase 2 | Not yet recruiting | Xianmin Song, MD | 45 | 2025-09-01 | 2025-08-06 |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases Inebilizumab, Blinatumomab - Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis | Phase 2 | Recruiting | Amgen | 220 | 2025-07-16 | 2026-10-05 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-11-18 |
Showing 20 of 102. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (47) · Burkitt Lymphoma (31) · Neoplasm, Residual (12) · Leukemia (10) · Recurrence (10) · Leukemia, Biphenotypic, Acute (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Leukemia, Lymphoid (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (4) · Immunoproliferative Disorders (3) · Blast Crisis (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)
M.D. Anderson Cancer Center (15) · Amgen (9) · Amgen Research (Munich) GmbH (6) · The First Affiliated Hospital of Soochow University (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · National Cancer Institute (NCI) (5) · St. Jude Children's Research Hospital (5) · Goethe University (4) · Assistance Publique - Hôpitaux de Paris (2) · Chen Suning (2) · First Affiliated Hospital of Zhejiang University (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Memorial Sloan Kettering Cancer Center (2) · Sichuan University (2) · Bambino Gesù Hospital and Research Institute (1)
United States (50) · China (21) · Germany (16) · France (15) · Italy (13) · Canada (9) · Spain (9) · Australia (8) · Belgium (7) · Netherlands (6) · United Kingdom (6) · Austria (5) · Puerto Rico (5) · Israel (4) · Japan (4)
Elias Jabbour (5) · Elias Jabbour, MD (4) · Nicola Goekbuget, MD (4) · Brandon Triplett, MD (2) · Max Topp, MD (2) · Suning Chen (2) · Xiaofan Zhu, MD (2) · A.W. Rijneveld, Dr. (1) · Alessandro Rambaldi (1) · Anjali S Advani (1) · Arend von Stackelberg, MD (1)
PMID 41671463, PMID 35622074, PMID 27209293, PMID 22592608, PMID 25192414, PMID 25385737, PMID 25524800, PMID 26755709, PMID 27873237, PMID 27998223, PMID 28533941, PMID 28859185, PMID 28922466, PMID 29352703, PMID 29358182, PMID 30254079, PMID 31648325, PMID 32546071, PMID 32619115, PMID 33085860, PMID 33191168, PMID 34914826, PMID 35503708, PMID 35713551, PMID 35941212, PMID 36279879, PMID 36322825, PMID 36402146, PMID 37131217, PMID 37141547, PMID 37187201, PMID 38127722, PMID 38135369, PMID 38551807, PMID 39028925, PMID 39218935, PMID 39984805, PMID 40009490, PMID 40369607, PMID 41026957, PMID 41592282, PMID 41979896, PMID 42126414, PMID 42154791
2016 (3), 2025 (3), U10CA180886 (3), 2017 (2), U10CA180888 (2), 2015 (1), 2023 (1), P30CA093373 (1), U10CA180821 (1)